Literature DB >> 18843722

Benzodiazepines for catatonia in people with schizophrenia and other serious mental illnesses.

Roger Carl Gibson1, Geoffery Walcott.   

Abstract

BACKGROUND: Catatonia is a debilitating disorder of movement and volition associated with schizophrenia and some other mental disorders. People in a catatonic state have increased risk of secondary complications such as pneumonia, malnutrition and dehydration. The mainstay of treatment has been drug therapies and electroconvulsive therapy.
OBJECTIVES: To compare the effects of benzodiazepines with other drugs, placebo or electroconvulsive therapy for people with catatonia. SEARCH STRATEGY: We searched the Cochrane Schizophrenia Group Trials Register (March 2007) and manually searched reference lists from the selected studies. SELECTION CRITERIA: All relevant randomised controlled clinical trials. DATA COLLECTION AND ANALYSIS: We (RCG, GW) extracted data independently. For dichotomous data we would have calculated relative risks (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis using a fixed-effect model. MAIN
RESULTS: No studies could be included. We did find studies reporting no usable data that we had to exclude or assign to those awaiting assessment. These studies, although poorly reported, do illustrate that relevant studies have been undertaken, and are not impossible. AUTHORS'
CONCLUSIONS: Studies have been justified and undertaken in the past. This justification remains as relevant as ever. Further studies with a high-quality methodology and reporting are required and it may be for countries where catatonia is seen often to take a lead in this area.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18843722     DOI: 10.1002/14651858.CD006570.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  6 in total

1.  Successful electroconvulsive therapy in a young woman with chronic catatonia.

Authors:  Heval Ozgen; Jaap Wijkstra; Jacob Vorstman
Journal:  Prim Care Companion CNS Disord       Date:  2012-06-21

2.  Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia".

Authors: 
Journal:  Neuropsychopharmacol Rep       Date:  2021-08-12

Review 3.  Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms.

Authors:  Michael W Huang; Roger Carl Gibson; Mahesh B Jayaram; Stanley N Caroff
Journal:  Cochrane Database Syst Rev       Date:  2022-07-12

4.  Using the needs of WHO to prioritise Cochrane reviews: The case of antipsychotic drugs.

Authors:  Marianna Purgato; Corrado Barbui; Clive E Adams
Journal:  Int J Ment Health Syst       Date:  2011-09-24

Review 5.  Systematic review of catatonia treatment.

Authors:  Anne Cm Pelzer; Frank Mma van der Heijden; Erik den Boer
Journal:  Neuropsychiatr Dis Treat       Date:  2018-01-17       Impact factor: 2.570

6.  Neuroleptic malignant syndrome following catatonia: Vigilance is the price of antipsychotic prescription.

Authors:  Thomas J Reilly; Sean Cross; David M Taylor; Richard Haslam; Sophie C Tomlin; Benjamin Gaastra
Journal:  SAGE Open Med Case Rep       Date:  2017-03-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.